Biodesix In The News

The white paper, “Innovative Validation and Regulatory Processes for Companion Diagnostic Tests for Rare Biomarkers for Indications,” was developed through a collaborative working group of dedicated experts who provided practical approaches for validating companion diagnostics for rare biomarkers, where traditional approaches may be impractical due to sample scarcity and other unique challenges.

The primary findings of the study demonstrated that the Nodify CDT test maintained a high specificity, meaning that a very low percentage of benign nodules were misclassified as high risk.

The Doximity community an exclusive, professional network for verified healthcare professionals, where members to connect, collaborate, and stay informed on medical news, research, and industry trends. Dr. Jett has articles on Doximity that have experienced over 20,000 citations!

Biodesix ranked #32 by the Healthcare Technology Report in the in Top 100 Healthcare Technology Companies of 2024.

Scott Hutton added to the Denver Dealmakers Hall of Fame by Smart Business Dealmakers for growing Biodesix into a leading diagnostics company with a strong company culture.

Robbie Lunt was recognized by BizWest as a professional under 40 years old, making a mark on his communities through professional success and volunteer activities.

Read the article focused on amplicon-based targeted NGS approaches, sponsored by Thermo Fisher Scientific.

Droplet Digital PCR performed at Biodesix was recently featured in two publications in The New England Journal of Medicine and Annals of Oncology related to Johnson and Johnson’s MARIPOSA non-small-cell lung cancer trial, where ddPCR was used to measure cancer mutations in participating patient samples

The June 2024 issue of Annals of Oncology includes a secondary analysis from MARIPOSA that highlights the role of Biodesix Diagnostic Services (using Bio-Rad Laboratories' trademarked ddPCR technology) in monitoring the efficacy of new therapeutic regimens.

The comprehensive Best Workplaces employee survey measured topics such as management effectiveness, perks, recognition, fostering employee growth, and overall company culture. The survey resulted in a 93% (highly) engaged employee score for Biodesix.

Scott Hutton explains the clinical value of Nodify Lung^® Nodule Risk Assessment testing and running a public life sciences diagnostics company with ProCO360 podcast host, David Tabor.

Newsweek ranked companied based on an analysis from data provided from market intelligence company Holon IQ on the impact of each business's product or service and the expertise of its leadership, and financial performance.

The ASCO "40 Under 40 in Cancer" is an initiative to identify and recognize the contributions being made across the field of cancer by rising stars and emerging leaders under the age of 40.

“Using the Nodify XL2 test in these patients may help us avoid unnecessary diagnostic procedures and delays, allowing us to safely proceed with needed emphysema treatments.” – Arthur Romero MD, MSC, FCCP, Associate Professor of Pulmonary and Critical Care Medicine at the University of Nevada Las Vegas.

Biodesix transforms former retail location to accelerate the design, manufacturing, and delivery of personalized diagnostics.

Biodesix was listed as a finalist in the Life Sciences category for the GeneStrat^® targeted tumor genomic profiling test and the VeriStrat^® immune profiling test.

Under Scott Hutton’s leadership, Biodesix has grown into a leading diagnostics company with a mission to transform patient care and improve outcomes through personalized diagnostics.

Chief Development Officer, Gary Pestano and Dr. Howard Scher of Memorial Sloan Kettering Cancer Research Center explain their approach for an effective R&D collaboration framework.

Friends of Cancer Research publication in MDPI's Journal Diagnostics featuring Biodesix evaluating ctDNA levels prior to cancer treatment to identify overall trends and considerations to inform the use of ctDNA in oncology drug development.

Biodesix highlights advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical value of rapid turnaround time to detect actionable tumor mutations in a real-world clinical setting.